Who Paid My Doc
Meera Gupta
Allergy & Immunology Galveston, TX Medical Doctor
NPI 1659548360 CMS profile 166258
301 University Blvd, Galveston, TX 77555
General payments
$51,214
Research payments
$7,451
Ownership & investment interest
$0
Research they led as principal investigator
$33,685
Through program year 2025, Meera Gupta of Galveston, TX is reported in the CMS Open Payments database as having received $51,214 across 143 general payments and $7,451 in research payments paid to them. Separately, studies naming them as principal investigator received $33,685 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 90th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $13,849 | 38 | |
| 2025 | Research | $4,642 | 12 | |
| 2024 | General | $16,168 | 33 | |
| 2024 | Research | $2,808 | 12 | |
| 2023 | General | $7,057 | 31 | |
| 2022 | General | $11,470 | 32 | |
| 2021 | General | $1,037 | 1 | |
| 2020 | General | $1,018 | 2 | |
| 2019 | General | $616 | 6 |
Beside peers
- Meera Gupta
- Allergy & Immunology median
- Middle half of Allergy & Immunology
- National median
In program year 2025, general payments to Meera Gupta were reported at $13,849. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.
Show as a table
| Year | Meera Gupta | Allergy & Immunology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $616 | $594 | $163–$1,512 | $163 |
| 2020 | $1,018 | $426 | $106–$1,233 | $114 |
| 2021 | $1,037 | $638 | $157–$1,708 | $132 |
| 2022 | $11,470 | $790 | $205–$1,961 | $149 |
| 2023 | $7,057 | $852 | $220–$2,147 | $160 |
| 2024 | $16,168 | $865 | $203–$2,267 | $164 |
| 2025 | $13,849 | $1,140 | $272–$2,892 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
167 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Allergy & Immunology in Texas
Joseph Diaz
Allergy & Immunology · San Antonio, TX
Richard Wasserman
Allergy & Immunology · Dallas, TX
Matthew Feldman
Allergy & Immunology · Dallas, TX
Lukena Karkhanis
Allergy & Immunology · San Antonio, TX
Paul Vigo
Allergy & Immunology · Austin, TX
Neha Reshamwala
Allergy & Immunology · Austin, TX
Related records
Allergy & Immunology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Allergy & Immunology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.